The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency

J Heart Lung Transplant. 2005 Oct;24(10):1517-21. doi: 10.1016/j.healun.2004.11.013.


Background: Lung transplantation is an established treatment for end-stage bronchiectasis. A proportion of patients with bronchiectasis have an associated antibody deficiency. This group benefits from immunoglobulin replacement therapy, but the outcome of lung transplantation is not known.

Methods: We conducted a retrospective observational study of all who received a transplant for bronchiectasis at our unit. We compared the survival after transplant, number of infective and rejection episodes, and the change in forced expiratory volume in 1 second (FEV1).

Results: Five of the 37 patients identified with bronchiectasis had an antibody deficiency that required immunoglobulin replacement therapy. Actuarial survival was similar in the 2 groups, being 81% at 12 months in the Bronchiectasis Group and 80% in the Antibody Deficiency Group. The FEV1 at 12 months after transplantation was similar in each group, with a predicted mean +/- SD FEV1 of 83.7% +/- 24.2% in those with bronchiectasis and 83.0% +/- 30.4% in those with antibody deficiency as well. The infection and rejection rates in the first year after transplantation were lower in the Antibody Deficiency Group. Infection episodes per 100 patient-days for bronchiectasis alone were 0.90 vs 0.53 and rejection episodes per 100 patient-days were 0.59 vs 0.24.

Conclusions: There was no evidence that transplant recipients with bronchiectasis and antibody deficiency have a worse prognosis than those with bronchiectasis alone.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Bronchiectasis / complications
  • Bronchiectasis / surgery*
  • Chemoprevention
  • Cytomegalovirus Infections / etiology
  • Female
  • Forced Expiratory Volume
  • Graft Rejection / etiology
  • Graft Rejection / prevention & control
  • Heart Transplantation
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Deficiency Syndromes / complications
  • Immunologic Deficiency Syndromes / surgery*
  • Immunosuppressive Agents / therapeutic use
  • Infections / etiology
  • Infections / therapy
  • Lung Transplantation*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome


  • Antifungal Agents
  • Antiviral Agents
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents